Exploiting Toll-like receptor (TLR) agonists or their certain combinations can enhance the immune potency of subunit vaccine. Nevertheless, the design of co-delivery systems which can act in a synergistic and spatio-temporal way to achieve effective and durable specific immune response is still challenging. Here we fabricated mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) for co-delivery of ovalbumin antigen both inside the inner core and outside the lipid layer, TLR7/8 agonist imiquimod within the hydrophobic membrane, TLR4 agonist monophosphoryl lipid A in the lipid layer as programmed nanovaccine to synergistically activate immune responses for improving vaccine efficacy. After efficiently internalized by dendritic cells via mannose targeting and TLR4 ligating, MAN-IMO-PS significantly enhanced cross-presentation and cytokine production. In addition, MAN-IMO-PS showed depot effect at the injection site and enhanced migration to draining lymph nodes. Mice immunized with MAN-IMO-PS elicited greater lymphocyte activation, CD4 + and CD8 + T cell response, effector cytokines secretion, and induced Th-1 biased humoral responses. More importantly, prophylactic vaccination by MAN-IMO-PS significantly delayed tumor occurrence, suppressed tumor growth with prolonged survival, and achieved long-term immune effect. The present study demonstrates a rationally designed nanovaccine for combining antigen, different TLR agonists, and targeting moiety in a programmed manner to induce synergistic antitumor immune response.
|Original language||English (US)|
|Number of pages||16|
|State||Published - Jun 2019|
Bibliographical noteFunding Information:
This work was financially supported by National Natural Science Foundation of China ( 81571793 , 81671806 , 51103180 , 81100100 ), CAMS Initiative for Innovative Medicine ( 2017-I2M-3-020 , 2017-I2M-4-001 ), Tianjin Municipal Natural Science Foundation ( 15JCZDJC38300 ).
- Antigen delivery
- Cancer vaccine
- Lipid-hybrid polymersomes
- Mannose-receptor targeting
- Monophosphoryl lipid A